Journal of Traditional Chinese Medicine ›› 2023, Vol. 43 ›› Issue (4): 640-649.DOI: 10.19852/j.cnki.jtcm.20230506.001
• Meta-analysises • Previous Articles Next Articles
Effect of Traditional Chinese Medicine combined with Western Medicine on blood lipid levels and inflammatory factors in patients with angina pectoris in coronary heart disease identified as intermingled phlegm and blood stasis syndrome: a network Meta-analysis
WANG Chao1,2, WU Qiong3, LI Ping4, WANG Zhigang5, LOU Xusheng4, LI Yuanyuan4, ZHANG Lin6(
)
- 1 Postdoctoral Mobile Station of Chinese Academy of Traditional Chinese medicine, Beijing 100700, China
2 China Academy of Chinese Medical Sciences, Beijing 100700, China
3 Zang-xiang Teaching and Research Department, the Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China
4 Department of Cardiovascular Medicine Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing 100029, China
5 Shandong College of Traditional Chinese Medicine, Yantai 264199, China
6 School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102488, China
-
Received:2022-03-29Accepted:2022-08-26Online:2023-08-15Published:2023-05-06 -
Contact:Prof. ZHANG Lin, School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102488, China, zhanglin@bucm.edu.cn. Telephone: +86-10-84068569 -
Supported by:Fundamental Research Funds for the Central Public Welfare Research Institutes: Theoretical Study of Combination of Facial Color and Pulses Mode in Traditional Chinese Medicine(KJ-202013);Objective Study of “Wei Qi” in Pulse Based on Color Doppler Flow Imaging (CDFI) Technology(YZ-202124)
Cite this article
WANG Chao, WU Qiong, LI Ping, WANG Zhigang, LOU Xusheng, LI Yuanyuan, ZHANG Lin. Effect of Traditional Chinese Medicine combined with Western Medicine on blood lipid levels and inflammatory factors in patients with angina pectoris in coronary heart disease identified as intermingled phlegm and blood stasis syndrome: a network Meta-analysis[J]. Journal of Traditional Chinese Medicine, 2023, 43(4): 640-649.
share this article
Figure 1 Literature search and selection CNKI: China National Knowledge Infrastructure; VIP: China Science and Technology Journal Database.
Figure 1 Literature search and selection CNKI: China National Knowledge Infrastructure; VIP: China Science and Technology Journal Database.
Table 1 Basic characteristics of included studies
| Included study | Sample size (n) | Follow-up time (weeks) | Intervention | Measures number | Outcome indicator | ||||
|---|---|---|---|---|---|---|---|---|---|
| T (Male/Female) | C (Male/Female) | T | C | T | C | ||||
| Diao YJ et al 2020 | 35 (19/16) | 35 (17/18) | 4 | MWD+CWM | CWM | 2 | 1 | ①② | |
| Wang ZG et al 2017 | 40 (24/16) | 40 (22/18) | 4 | MWD+CWM | CWM | 2 | 1 | ① | |
| Li FG et al 2017 | 40 (21/19) | 40 (17/23) | 12 | MWD+CWM | CWM | 2 | 1 | ① | |
| Luo G,Ye HL 2017 | 30- | 30- | 4 | MWD+CWM | CWM | 2 | 1 | ②⑦ | |
| Hou BS et al 2018 | 30 (18/12) | 30 (19/11) | 2 | MXD+CWM | CWM | 3 | 1 | ① | |
| Guan F et al 2018 | 50 (29/21) | 50 (34/16) | 4 | MXD+CWM | CWM | 3 | 1 | ②⑦ | |
| Ou XX et al 2021 | 82 (43/39) | 80 (41/39) | 2 | MGXBD+CWM | CWM | 4 | 1 | ③④⑤⑥ | |
| Qiu WF, Luo JQ 2021 | 42 (23/19) | 42 (21/21) | 4 | MGXBD+CWM | CWM | 4 | 1 | ② | |
| Tian PP et al 2021 | 40 (24/16) | 40 (26/14) | 4 | MGXBD+CWM | CWM | 4 | 1 | ①③④⑤⑥⑦ | |
| Gong XT et al 2021 | 35 (23/12) | 35 (24/11) | 4 | MGXBD+CWM | CWM | 4 | 1 | ①③④⑤⑥ | |
| Hu XQ 2020 | 57 (35/22) | 57 (39/18) | 4 | MGXBD+CWM | CWM | 4 | 1 | ①③④⑤⑥⑦ | |
| Wang M et al 2020 | 80 (44/36) | 80 (42/38) | 4 | MGXBD+CWM | CWM | 4 | 1 | ①③④⑤⑥ | |
| Zhu R et al 2020 | 42 (25/17) | 42 (26/16) | 4 | MGXBD+CWM | CWM | 4 | 1 | ①⑦ | |
| Xu JJ et al 2017 | 48 (26/22) | 48 (24/24) | 4 | MGXBD+CWM | CWM | 4 | 1 | ①②③④⑤⑥⑦ | |
| Dong LG et al 2021 | 48 (23/25) | 48 (22/26) | 16 | MED+CWM | CWM | 5 | 1 | ②③④⑤⑥ | |
| Hu F et al 2021 | 38 (20/18) | 38 (21/17) | 12 | MED+CWM | CWM | 5 | 1 | ①②③④⑤⑥ | |
| Bai YM, Huang L 2019 | 40 (22/18) | 40 (22/19) | 4 | MED+CWM | CWM | 5 | 1 | ③④⑤⑥ | |
| Yuan QY et al 2021 | 81 (48/33) | 80 (46/34) | 2 | MZXGD+CWM | CWM | 6 | 1 | ①⑦ | |
| Li FT et al 2021 | 34 (19/15) | 34 (18/16) | 8 | MZXGD+CWM | CWM | 6 | 1 | ①② | |
| Li M et al 2021 | 35- | 35- | 4 | MZXGD+CWM | CWM | 6 | 1 | ①③④⑤⑥ | |
| Tan XD et al 2019 | 51 (32/19) | 51 (34/17) | 4 | MZXGD+CWM | CWM | 6 | 1 | ①③④⑤ | |
| Liu Y et al 2018 | 73 - | 72- | 4 | MZXGD+CWM | CWM | 6 | 1 | ①③④⑤⑥ | |
| Zhai H et al 2019 | 52 (33/19) | 52 (32/20) | 6 | DT+CWM | CWM | 7 | 1 | ① | |
| Yang K 2019 | 33 (19/14) | 33 (17/16) | 52 | DT+CWM | CWM | 7 | 1 | ①⑦ | |
| Zhang JH et al 2018 | 45 (22/23) | 45 (24/21) | 6 | DT+CWM | CWM | 7 | 1 | ③④⑤⑥ | |
| Chen JF et al 2018 | 98 (57/42) | 99 (54/44) | 4 | DT+CWM | CWM | 7 | 1 | ① | |
| Diao YJ et al 2020 | 35 (19/16) | 35 (17/18) | 4 | MWD+CWM | CWM | 2 | 1 | ② | |
Table 1 Basic characteristics of included studies
| Included study | Sample size (n) | Follow-up time (weeks) | Intervention | Measures number | Outcome indicator | ||||
|---|---|---|---|---|---|---|---|---|---|
| T (Male/Female) | C (Male/Female) | T | C | T | C | ||||
| Diao YJ et al 2020 | 35 (19/16) | 35 (17/18) | 4 | MWD+CWM | CWM | 2 | 1 | ①② | |
| Wang ZG et al 2017 | 40 (24/16) | 40 (22/18) | 4 | MWD+CWM | CWM | 2 | 1 | ① | |
| Li FG et al 2017 | 40 (21/19) | 40 (17/23) | 12 | MWD+CWM | CWM | 2 | 1 | ① | |
| Luo G,Ye HL 2017 | 30- | 30- | 4 | MWD+CWM | CWM | 2 | 1 | ②⑦ | |
| Hou BS et al 2018 | 30 (18/12) | 30 (19/11) | 2 | MXD+CWM | CWM | 3 | 1 | ① | |
| Guan F et al 2018 | 50 (29/21) | 50 (34/16) | 4 | MXD+CWM | CWM | 3 | 1 | ②⑦ | |
| Ou XX et al 2021 | 82 (43/39) | 80 (41/39) | 2 | MGXBD+CWM | CWM | 4 | 1 | ③④⑤⑥ | |
| Qiu WF, Luo JQ 2021 | 42 (23/19) | 42 (21/21) | 4 | MGXBD+CWM | CWM | 4 | 1 | ② | |
| Tian PP et al 2021 | 40 (24/16) | 40 (26/14) | 4 | MGXBD+CWM | CWM | 4 | 1 | ①③④⑤⑥⑦ | |
| Gong XT et al 2021 | 35 (23/12) | 35 (24/11) | 4 | MGXBD+CWM | CWM | 4 | 1 | ①③④⑤⑥ | |
| Hu XQ 2020 | 57 (35/22) | 57 (39/18) | 4 | MGXBD+CWM | CWM | 4 | 1 | ①③④⑤⑥⑦ | |
| Wang M et al 2020 | 80 (44/36) | 80 (42/38) | 4 | MGXBD+CWM | CWM | 4 | 1 | ①③④⑤⑥ | |
| Zhu R et al 2020 | 42 (25/17) | 42 (26/16) | 4 | MGXBD+CWM | CWM | 4 | 1 | ①⑦ | |
| Xu JJ et al 2017 | 48 (26/22) | 48 (24/24) | 4 | MGXBD+CWM | CWM | 4 | 1 | ①②③④⑤⑥⑦ | |
| Dong LG et al 2021 | 48 (23/25) | 48 (22/26) | 16 | MED+CWM | CWM | 5 | 1 | ②③④⑤⑥ | |
| Hu F et al 2021 | 38 (20/18) | 38 (21/17) | 12 | MED+CWM | CWM | 5 | 1 | ①②③④⑤⑥ | |
| Bai YM, Huang L 2019 | 40 (22/18) | 40 (22/19) | 4 | MED+CWM | CWM | 5 | 1 | ③④⑤⑥ | |
| Yuan QY et al 2021 | 81 (48/33) | 80 (46/34) | 2 | MZXGD+CWM | CWM | 6 | 1 | ①⑦ | |
| Li FT et al 2021 | 34 (19/15) | 34 (18/16) | 8 | MZXGD+CWM | CWM | 6 | 1 | ①② | |
| Li M et al 2021 | 35- | 35- | 4 | MZXGD+CWM | CWM | 6 | 1 | ①③④⑤⑥ | |
| Tan XD et al 2019 | 51 (32/19) | 51 (34/17) | 4 | MZXGD+CWM | CWM | 6 | 1 | ①③④⑤ | |
| Liu Y et al 2018 | 73 - | 72- | 4 | MZXGD+CWM | CWM | 6 | 1 | ①③④⑤⑥ | |
| Zhai H et al 2019 | 52 (33/19) | 52 (32/20) | 6 | DT+CWM | CWM | 7 | 1 | ① | |
| Yang K 2019 | 33 (19/14) | 33 (17/16) | 52 | DT+CWM | CWM | 7 | 1 | ①⑦ | |
| Zhang JH et al 2018 | 45 (22/23) | 45 (24/21) | 6 | DT+CWM | CWM | 7 | 1 | ③④⑤⑥ | |
| Chen JF et al 2018 | 98 (57/42) | 99 (54/44) | 4 | DT+CWM | CWM | 7 | 1 | ① | |
| Diao YJ et al 2020 | 35 (19/16) | 35 (17/18) | 4 | MWD+CWM | CWM | 2 | 1 | ② | |
Figure 2 Network evidence results A: overall response rate; B: hs-CRP expression; C: TC; D: TG; E: LDL-C; F: HDL-C; G: duration of angina attack. MXD: modified Xiaoxianxiong decoction; DT: Danlou tablet; MGXBD: modified Gualou Xiebai Banxia decoction; MWD: modified Wendan decoction; MZXGD: modified Zhishi Xiebai Guizhi decoction; MED: modified Erchen decoction; CWM: Conventional Western Medicine. hs-CRP: hypersensitive C-reactive protein; TC: total cholesterol; TG: triglyceride; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol.
Figure 2 Network evidence results A: overall response rate; B: hs-CRP expression; C: TC; D: TG; E: LDL-C; F: HDL-C; G: duration of angina attack. MXD: modified Xiaoxianxiong decoction; DT: Danlou tablet; MGXBD: modified Gualou Xiebai Banxia decoction; MWD: modified Wendan decoction; MZXGD: modified Zhishi Xiebai Guizhi decoction; MED: modified Erchen decoction; CWM: Conventional Western Medicine. hs-CRP: hypersensitive C-reactive protein; TC: total cholesterol; TG: triglyceride; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol.
Figure 3 Area under the curve ranking results A: overall response rate; B: hs-CRP expression; C: TC; D: TG; E: LDL-C; F: HDL-C; G: duration of angina attack. MXD: modified Xiaoxianxiong decoction; DT: Danlou tablet; MGXBD: modified Gualou Xiebai Banxia decoction; MWD: modified Wendan decoction; MZXGD: modified Zhishi Xiebai Guizhi decoction; MED: modified Erchen decoction; CWM: Conventional Western Medicine. hs-CRP: hypersensitive C-reactive protein; TC: total cholesterol; TG: triglyceride; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol.
Figure 3 Area under the curve ranking results A: overall response rate; B: hs-CRP expression; C: TC; D: TG; E: LDL-C; F: HDL-C; G: duration of angina attack. MXD: modified Xiaoxianxiong decoction; DT: Danlou tablet; MGXBD: modified Gualou Xiebai Banxia decoction; MWD: modified Wendan decoction; MZXGD: modified Zhishi Xiebai Guizhi decoction; MED: modified Erchen decoction; CWM: Conventional Western Medicine. hs-CRP: hypersensitive C-reactive protein; TC: total cholesterol; TG: triglyceride; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol.
Table 2 Network Meta-analysis comparisons of overall response rate (lower left) vs hs-CRP (upper right) (OR/MD value vs 95% CI)
| CWM | 0.66 (0.10, 1.22)a | 1.98 (1.26, 2.70)a | 0.43 (0.06, 0.79)a | 1.89 (1.46, 2.33)a | 3.02 (2.32, 3.72)a | — |
|---|---|---|---|---|---|---|
| 0.29 (0.13, 0.65)a | MWD | 1.32 (0.41, 2.23)a | -0.23 (-0.90, 0.44) | 1.23 (0.52, 1.94)a | 2.36 (1.46, 3.26)a | — |
| 0.20 (0.04, 1.02) | 0.69 (0.11, 4.34) | MXD | -1.55 (-2.36, -0.75)a | -0.09 (-0.93, 0.75) | 1.04 (0.04, 2.04)a | — |
| 0.27 (0.17, 0.45)a | 0.96 (0.37, 2.49) | 1.39 (0.25, 7.74) | MGXBD | 1.46 (0.90, 2.03)a | 2.59 (1.80, 3.38)a | — |
| 0.29 (0.09, 0.92)a | 1.02 (0.25, 4.22) | 1.48 (0.20, 11.09) | 1.07 (0.30, 3.75) | MED | 1.13 (0.30, 1.95)a | — |
| 0.28 (0.17, 0.47)a | 0.99 (0.37, 2.61) | 1.43 (0.26, 8.06) | 1.03 (0.51, 2.11) | 0.97 (0.27, 3.42) | MZXGD | — |
| 0.25 (0.13, 0.49)a | 0.89 (0.31, 2.56) | 1.29 (0.22, 7.63) | 0.93 (0.41, 2.13) | 0.87 (0.23, 3.30) | 0.90 (0.39, 2.08) | DT |
Table 2 Network Meta-analysis comparisons of overall response rate (lower left) vs hs-CRP (upper right) (OR/MD value vs 95% CI)
| CWM | 0.66 (0.10, 1.22)a | 1.98 (1.26, 2.70)a | 0.43 (0.06, 0.79)a | 1.89 (1.46, 2.33)a | 3.02 (2.32, 3.72)a | — |
|---|---|---|---|---|---|---|
| 0.29 (0.13, 0.65)a | MWD | 1.32 (0.41, 2.23)a | -0.23 (-0.90, 0.44) | 1.23 (0.52, 1.94)a | 2.36 (1.46, 3.26)a | — |
| 0.20 (0.04, 1.02) | 0.69 (0.11, 4.34) | MXD | -1.55 (-2.36, -0.75)a | -0.09 (-0.93, 0.75) | 1.04 (0.04, 2.04)a | — |
| 0.27 (0.17, 0.45)a | 0.96 (0.37, 2.49) | 1.39 (0.25, 7.74) | MGXBD | 1.46 (0.90, 2.03)a | 2.59 (1.80, 3.38)a | — |
| 0.29 (0.09, 0.92)a | 1.02 (0.25, 4.22) | 1.48 (0.20, 11.09) | 1.07 (0.30, 3.75) | MED | 1.13 (0.30, 1.95)a | — |
| 0.28 (0.17, 0.47)a | 0.99 (0.37, 2.61) | 1.43 (0.26, 8.06) | 1.03 (0.51, 2.11) | 0.97 (0.27, 3.42) | MZXGD | — |
| 0.25 (0.13, 0.49)a | 0.89 (0.31, 2.56) | 1.29 (0.22, 7.63) | 0.93 (0.41, 2.13) | 0.87 (0.23, 3.30) | 0.90 (0.39, 2.08) | DT |
Table 3 Network Meta—analysis comparisons of TC (lower left) vs TG (upper right) (MD value vs 95% CI)
| CWM | 0.49 (0.12, 0.86)a | 1.23 (0.72, 1.75)a | 1.16 (0.62, 1.71)a | 0.33 (—0.55, 1.21) |
|---|---|---|---|---|
| 0.73 (0.21, 1.24)a | MGXBD | 0.74 (0.11, 1.38)a | 0.68 (0.02, 1.33)a | —0.16 (—1.11, 0.80) |
| 0.89 (0.18, 1.61)a | 0.17 (—0.72, 1.05) | MED | —0.07 (—0.82, 0.68) | —0.90 (—1.92, 0.12) |
| 1.41 (0.68, 2.14)a | 0.68 (—0.21, 1.58) | 0.52 (—0.51, 1.54) | MZXGD | —0.83 (—1.87, 0.20) |
| 0.76 (—0.48, 2.00) | 0.03 (—1.31, 1.38) | —0.13 (—1.57, 1.30) | —0.65 (—2.10, 0.79) | DT |
Table 3 Network Meta—analysis comparisons of TC (lower left) vs TG (upper right) (MD value vs 95% CI)
| CWM | 0.49 (0.12, 0.86)a | 1.23 (0.72, 1.75)a | 1.16 (0.62, 1.71)a | 0.33 (—0.55, 1.21) |
|---|---|---|---|---|
| 0.73 (0.21, 1.24)a | MGXBD | 0.74 (0.11, 1.38)a | 0.68 (0.02, 1.33)a | —0.16 (—1.11, 0.80) |
| 0.89 (0.18, 1.61)a | 0.17 (—0.72, 1.05) | MED | —0.07 (—0.82, 0.68) | —0.90 (—1.92, 0.12) |
| 1.41 (0.68, 2.14)a | 0.68 (—0.21, 1.58) | 0.52 (—0.51, 1.54) | MZXGD | —0.83 (—1.87, 0.20) |
| 0.76 (—0.48, 2.00) | 0.03 (—1.31, 1.38) | —0.13 (—1.57, 1.30) | —0.65 (—2.10, 0.79) | DT |
Table 4 Network Meta—analysis comparisons of LDL—C (lower left) vs HDL—C (upper right) (MD value vs 95% CI)
| CWM | —0.17 (—0.27, —0.07)a | —0.47 (—0.60, —0.34)a | —0.23 (—0.46, —0.01)a | —0.05 (—0.25, 0.15) |
|---|---|---|---|---|
| 0.66 (0.34, 0.98)a | MGXBD | —0.30 (—0.47, —0.14)a | —0.06 (—0.31, 0.18) | 0.12 (—0.10, 0.35) |
| 0.51 (0.06, 0.96)a | —0.14 (—0.69, 0.41) | MED | 0.24 (—0.02, 0.50) | 0.42 (0.19, 0.66)a |
| 1.00 (0.52, 1.48)a | 0.34 (—0.24, 0.92) | 0.49 (—0.17, 1.15) | MZXGD | 0.18 (—0.12, 0.48) |
| 0.66 (—0.10, 1.42) | 0.00 (—0.82, 0.83) | 0.15 (—0.73, 1.03) | —0.34 (—1.24, 0.56) | DT |
Table 4 Network Meta—analysis comparisons of LDL—C (lower left) vs HDL—C (upper right) (MD value vs 95% CI)
| CWM | —0.17 (—0.27, —0.07)a | —0.47 (—0.60, —0.34)a | —0.23 (—0.46, —0.01)a | —0.05 (—0.25, 0.15) |
|---|---|---|---|---|
| 0.66 (0.34, 0.98)a | MGXBD | —0.30 (—0.47, —0.14)a | —0.06 (—0.31, 0.18) | 0.12 (—0.10, 0.35) |
| 0.51 (0.06, 0.96)a | —0.14 (—0.69, 0.41) | MED | 0.24 (—0.02, 0.50) | 0.42 (0.19, 0.66)a |
| 1.00 (0.52, 1.48)a | 0.34 (—0.24, 0.92) | 0.49 (—0.17, 1.15) | MZXGD | 0.18 (—0.12, 0.48) |
| 0.66 (—0.10, 1.42) | 0.00 (—0.82, 0.83) | 0.15 (—0.73, 1.03) | —0.34 (—1.24, 0.56) | DT |
Table 5 Network Meta—analysis comparisons of duration of angina attack (MD value vs 95% CI)
| CWM | |||||
|---|---|---|---|---|---|
| 0.85 (—0.18, 1.88) | MWD | ||||
| —0.49 (—1.98, 1.00) | —1.34 (—3.16, 0.48) | MXD | |||
| 1.54 (1.00, 2.07)a | 0.69 (—0.48, 1.85) | 2.03 (0.44, 3.62)a | MGXBD | ||
| 2.14 (1.09, 3.19)a | 1.29 (—0.18, 2.76) | 2.63 (0.80, 4.46)a | 0.60 (—0.58, 1.78) | MZXGD | |
| 0.97 (—0.11, 2.05) | 0.12 (—1.38, 1.62) | 1.46 (—0.38, 3.30) | —0.57 (—1.78, 0.64) | —1.17 (—2.68, 0.34) | DT |
Table 5 Network Meta—analysis comparisons of duration of angina attack (MD value vs 95% CI)
| CWM | |||||
|---|---|---|---|---|---|
| 0.85 (—0.18, 1.88) | MWD | ||||
| —0.49 (—1.98, 1.00) | —1.34 (—3.16, 0.48) | MXD | |||
| 1.54 (1.00, 2.07)a | 0.69 (—0.48, 1.85) | 2.03 (0.44, 3.62)a | MGXBD | ||
| 2.14 (1.09, 3.19)a | 1.29 (—0.18, 2.76) | 2.63 (0.80, 4.46)a | 0.60 (—0.58, 1.78) | MZXGD | |
| 0.97 (—0.11, 2.05) | 0.12 (—1.38, 1.62) | 1.46 (—0.38, 3.30) | —0.57 (—1.78, 0.64) | —1.17 (—2.68, 0.34) | DT |
Figure 4 Comparison-correction funnel plot of clinical effects
Figure 4 Comparison-correction funnel plot of clinical effects
| 1. | Yang YJ, Hua W. Fuwai hand book of cardiovascular medicine. Beijing: Ren Min Wei Sheng Chu Ban She 2006; 117-32. |
| 2. | Liang XF. Observation of treating 82 cases of angina pectoris with phlegm and Stasis. Shi Yong Zhong Yi Nei Ke Za Zhi 2007; 21: 73. |
| 3. | Li XT. Understanding of clinical syndrome differentiation of coronary heart disease with phlegm and blood stasis syndrome (chest obstruction and heartache). Liaoning Zhong Yi Za Zhi 2016; 43: 10-2. |
| 4. | Cao HX, Zhang HM. Interaction of phlegm and blood stasis and identification of pathogenesis of coronary heart disease. Zhong Hua Zhong Yi Yao Xue Kan 2001; 19: 544-6. |
| 5. | Jia LQ, Zhang N, Song N, Zhang HY, Yang GL. Modern biological basis on coronary heart disease (CHD) of phlegm turbidity and blood stasis syndrome from unsmoothness of vessels. Zunyi Yi Xue Yuan Xue Bao 2015; 38: 337-40. |
| 6. | Chen GQ, Wu JX, Chen XL, Huang AW. Correlation between serum homocysteine and hypersensitive C-reactive protein levels and coronary artery disease in patients with coronary heart disease. Guangdong Yi Ke Da Xue Xue Bao 2019; 3: 461-3. |
| 7. | Duan XJ, Wu JR, Huang XY, et al. Comparative efficacy of Chinese herbal injections for treating acute exacerbation of chronic obstructive pulmonary disease: a Bayesian network Meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med 2018; 2018: 7942936. |
| 8. | Joint task Group of international Cardiology Societies and associations and the World Health Organization on Clinical Nomenclature Standards. Nomenclature and diagnostic criteria for ischemic heart disease. Zhong Hua Xin Xue Guan Bing Za Zhi 1981; 9: 75-7. |
| 9. | Ministry of Health, PRC. Guiding principles for clinical research of new Chinese medicine. Beijing: Zhong Guo Yi Yao Ke Ji Chu Ban She, 2002: 41-5. |
| 10. | Discussion on treatment of angina pectoris and arrhythmia of coronary heart disease by integrated Chinese and Western Medicine. Evaluation standard of coronary heart disease angina pectoris and electrocardiogram. Zhong Guo Yao Shi 1987; 1: 71. |
| 11. | Zheng XY. Clinical research guidelines of new Chinese medicine in treating angina pectoris of coronary heart disease. Beijing: Zhong Guo Yi Yao Ke Ji Chu Ban She, 2002: 68-73. |
| 12. |
Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
DOI URL |
| 13. |
Bangalore S, Toklu B, Stone GW. Meta-analysis of culprit-only versus multivessel percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction and multivessel coronary disease. Am J Cardiol 2018; 121: 529-36.
DOI PMID |
| 14. | Zhang TS. Practical evidence-based medicine methodology. Hunan: Zhong Nan Da Xue Chu Ban She, 2014: 228-37. |
| 15. | Diao YJ, Sun SM, Liang N, Zhao F, Song LC, Dong J. Effect of Wendan decoction on clinical efficacy and hs-CRP in patients with coronary heart disease complicated with phlegm-heat and blood stasis syndrome. Jilin Zhong Yi Yao 2020; 40: 193-6. |
| 16. | Wang ZG, Wen XF, Zhao H. Clinical observation of Wendan decoction and Sijunzi decoction in treating Qi deficiency and phlegm stasis syndrome of stable angina pectoris of coronary heart disease. Xin Zhong Yi 2017; 49: 20-2. |
| 17. | Li FE, Qiang LX, Sun CY, Wang QX. Liu Yujie use clinical observation of 40 cases of coronary heart disease with depression after PCI treated with Wendan decoction. Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi 2017; 15: 2766-8. |
| 18. | Luo G, Ye SL. Observation on curative effect of Huanglian Wendan decoction in treating patients with stable angina pectoris of coronary heart disease. Zhong Guo Zhong Yi Ji Zheng 2017; 26: 520-2. |
| 19. | Hou BS, Li XH, Liu X, Song YQ, Zhan WY, Wang HF. Clinical study on treatment of Angina pectoris with phlegm-heat and blood stasis type coronary heart disease by Xiaoxianxiong decoction. Henan Zhong Yi 2018; 38: 201-5. |
| 20. | Guan F, Guo X. Clinical observation on treating angina pectoris with phlegm-heat interaction after coronary stenting with Xiao xianxiong decoction. Zhong Yi Yao Dao Bao 2018; 24: 110-2. |
| 21. | Ou XX, Long Y, Wang YA. Effect of Gualou Xiebai Banxia decoction on 2D-STE and IVUS indexes in patients with phlegm turbidity syndrome of coronary heart disease. Jilin Zhong Yi Yao 2021; 41: 1600-4. |
| 22. | Qiu WF, Lao JQ. Effect of Gualou Xiebai Banxia decoction combined with atorvastatin on angina pectoris of coronary heart disease and its effect on micro-inflammatory response of patients. Hainan Yi Xue 2021; 32: 2197-200. |
| 23. | Tian PP, Li J, Chen HW, Wu QJ, Zhao W, Tan YQ. Clinical study of Gualou Xiebai Banxia decoction and Danshen decoction in the treatment of phlegm and blood stasis syndrome of unstable angina pectoris. Hainan Yi Xue Yuan Xue Bao 2021; 27: 1059-1063. |
| 24. | Gong XT, Chen LM, Li ZC, He ZH. Clinical study of Gualou Xiebai Banxia decoction combined with Shixiao San in treatment of coronary heart disease angina pectoris. Shanxi Zhong Yi 2021; 42: 886-9. |
| 25. | Hu XQ. Buyang Huanwu decoction and Gualou Xiebai Banxia decoction for coronary atherosclerotic heart disease angina pectoris treatment. Henan Zhong Yi 2020; 40: 225-8. |
| 26. | Wang M, Yu XH, Zhang JQ. Clinical study of Gualou Xiebai Banxia decoction combined with atorvastatin in the treatment of patients with phlegm and turbidity obstruction of coronary heart disease. Shi Jie Zhong Xi Yi Jie He Za Zhi 2020; 15: 147-50. |
| 27. | Zhu R, Han Y, He Y. Zhang J. Clinical study of Gualou Xiebai Banxia decoction and modified Xuefu Zhuyu decoction combined with Western Medicine in treating chest pain. Sichuan Zhong Yi 2020; 38: 95-8. |
| 28. | Xu JJ, Qiu J, Zhang GH. Guo HJ. Clinical analysis of Gualou Xiebai Banxia decoction combined with Xuefu Zhuyu decoction in treating angina pectoris of coronary heart disease. Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi 2017; 15: 2277-80. |
| 29. | Dong LG, Wang FM, Mao PA, Huang FB. Effects of Erchen decoction plus statins on blood lipid, hs-CRP, TNF-α and IL-18 in elderly patients with coronary heart disease complicated with hyperlipidemia. Zhong Guo Zhong Yi Yao Ke Ji 2021; 28: 702-4, 68. |
| 30. | Hu F, Shen JF, Liu ZY. Effects of Liujunzi decoction and Erchen decoction on Hcy, NO and hs-CRP in patients with coronary heart disease. Zhong Guo Shi Yan Fang Ji Xue Za Zhi 2020; 26: 24-9. |
| 31. | Bai YM, Huang L. Clinical effect of Erchen decoction and Xuefu Zhuyu decoction on angina pectoris of phlegm-stasis inter-junction coronary atherosclerotic heart disease. Zhong Guo Yi Yao 2019; 14: 659-63. |
| 32. | Yuan QY, Gan X, Bao HG, Li ZW, Liu XX, Li L. Effects of Zhishi Xiebai Guizhi decoction on serum inflammatory factors and vascular endothelial function in patients with unstable angina pectoris of phlegm interaction coronary heart disease. Zhong Hua Zhong Yi Yao Za Zhi 2021; 36: 6893-7. |
| 33. | Li FT, Liu DD. Clinical study of modified Zhishi Xiebai Guizhi decoction in treating stable coronary heart disease with phlegm blocking heart vessel syndrom. Henan Zhong Yi 2021; 41: 1003-6. |
| 34. | Li M, Zhu H, Mei L, Liu P. The secondary prevention effect of Zhishi Xiebaiguzhi decoction and statins on stable angina pectoris complicated with hyperlipidemia of coronary heart disease. Guangzhou Zhong Yi Yao Da Xue Xue Bao 2021; 38: 1583-7. |
| 35. | Tan XD, Su W, Gao F, Lu S. Observation on the curative effect of Zhishi Xiebai Guizhi decoction on phlegm turbidity type coronary heart disease. Sichuan Zhong Yi 2019; 37: 79-82. |
| 36. | Liu Y, Shao JB, Guo LZ. Effect of Zhishi Xiebai Guizhi decoction on coronary heart disease complicated with hyperlipidemia and its effect on endothelial function and lipid metabolism. Zhong Yao Cai 2018; 41: 476-8. |
| 37. | Zhai H, Li T, Wang Y, Liu YW, Li X. Clinical study of Danlou tablet combined with Bisoprolol in treating angina pectoris of coronary heart disease. Zhong Hua Zhong Yi Yao Xue Kan 2019; 34: 341-5. |
| 38. | Yang K. Clinical observation of Danlou tablet combined with aspirin in treating elder people angina pectoris of coronary heart disease. Zhong Hua Zhong Yi Yao Xue Kan 2019; 37: 369-71. |
| 39. | Zhang JH, Zhao ZH, Li HX, Yan SY. Effect of Danlou tablet on blood lipid and hemorheology in patients with coronary heart disease complicated with hyperlipidemia. Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi 2018; 16: 1319-23. |
| 40. | Chen JF, Lei ZY, Liu CF, et al. Effect of Danlou tablet on phlegm-stasis syndrome of coronary heart disease and its effect on serum inflammatory factors. Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi 2018; 16: 3401-4. |
| 41. | Yuan ZK, Huang XP, Wang LP, Wang P, Wang DS. Clinical study on the characteristics of phlegm stasis syndrome in coronary heart disease. Yunnan Zhong Yi Xue Yuan Xue Bao 2011; 34: 3-7. |
| 42. | Yao CL, Li Y, Lu XJ, Jiang XJ. Relationship between super-oxide dismutase, its isoenzyme and hypersensitive C-reactive protein and coronary heart disease. Xian Dai Jian Yan Yi Xue Za Zhi 2016; 31: 73-5. |
| 43. | Lu Y, Peng JJ. Clinical significance of serum SOD detection in patients with coronary heart disease. Henan Da Xue Xue Bao 2019; 38: 201-3. |
| 44. |
Zhang Z, Chen A, Yu T, et al. Exploring the pharmacological mechanism of Danhe granules against hyperlipidemia by means of network pharmacology and verified by preliminary experiments. World J Tradit Chin Med 2021; 7: 436-44.
DOI URL |
| 45. | Zhang X, Li X, Zhou GF, et al. Research of molecular mechanism of Zhishi Xiebai Guizhi decoction on coronary heart disease treatment based on network pharmacology. Hunan Zhong Yi Yao Da Xue Xue Bao 2020; 40: 571-7. |
| 46. | Wang XL, Qin ZJ, Lu YH. Application of Stata software in network Meta-analysis. Xian Dai Yu Fang Yi Xue 2016; 43: 3461-4. |
| [1] | QIN Xiaoyu, WANG Chunai, XUE Jianjun, ZHANG Jie, LU Xiaoting, DING Shengshuang, GE Long, WANG Minzhen. Efficacy of electroacupuncture on myocardial protection and postoperative rehabilitation in patients undergoing cardiac surgery with cardiopulmonary bypass: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 1-15. |
| [2] | DAI Xiaoling, ZHANG Anming, LIN Hui, SHI Bei, REN Yi, WEN Hongzhu, FEI Xiaoyan, LIN Jiang. Qingchang suppositry (清肠栓) induced remission in patients with mild-to-moderate ulcerative proctitis: a multicenter, prospective, randomized, parallel-controlled clinical trial [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 156-162. |
| [3] | WANG Yichen, WU Shiyi, WANG Zhengyan, CHANG Wenling, XIE Zhihao, TANG Xing, ZHAO Songmei, ZHOU Jing, CHEN Zehong, WANG Chao, YANG Chunxia. Efficacy of Zhumian Tang formula granules (助眠汤配方颗粒) combined with eszopiclone for the treatment of poor sleep quality: a multi-center, randomized controlled, superiority trial [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 163-171. |
| [4] | YANG Yi, YE Huijun, ZHENG Huiling, JIN Lihua. Clinical observation on 90 cases of primary dysmenorrhea treated by buccal acupuncture therapy: a randomized controlled study [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 172-181. |
| [5] | DAI Zeqi, LIAO Xing, GUAN Yueyue, ZENG Zixiu, TANG Jun, HU Jing. Bloodletting puncture in the treatment of acute ischemic stroke: protocol for a mixed-method study of a multi-center randomized controlled trial and focus group [J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1259-1267. |
| [6] | XU Yani, ZHANG Yutong, HE Weile, DAI Linglin, TANG Ding, WANG Jialing, ZHANG Xufen, CHEN Qin, CHEN Lifang, WANG Zhanglian, ZHAN Mingjie. Efficiency and safety of acupuncture for women with premature ovarian insufficiency: study protocol for a randomized controlled trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1268-1274. |
| [7] | HAN Huagang, LI Ziqiang, OUYANG Jingfeng, WANG Tianquan, DONG Lingyan, CAO Junling. Mechanism of Lingbao Huxin Dan (灵宝护心丹) in the treatment of bradyarrhythmia complicated with coronary heart disease: a network pharmacology analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(5): 1001-1009. |
| [8] | XU Xiangru, ZHOU Yi, CHEN Gang, LEI Ming, ZHANG Wen, WU Xinxin, PU Yuting, CHEN Caiyu, SUN Yuting, ZHOU Shuang, FANG Bangjiang. Clinical efficacy of Buzhong Yiqi decoction (补中益气汤) in the treatment of hospital-acquired pneumonia with multi-drug resistant bacteria: a prospective, randomized, multicenter controlled trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(5): 1010-1018. |
| [9] | ZHAO Ming, LUO Yimiao, WANG Huichan, CAO Yu, MA Lina, PEI Hui, LI Hao. Guilingji capsule (龟龄集胶囊) for Alzheimer's disease: secondary analysis of a randomized non-inferiority controlled trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(5): 1019-1025. |
| [10] | ZHANG Meizhen, HAO Xiaohui, TANG Yiting, CHEN Yupeng, HE Puyu, ZHAO Liming, PANG Bing, NI Qing. Efficacy and safety of Buyang Huanwu decoction (补阳还五汤) for diabetic peripheral neuropathy: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(5): 841-850. |
| [11] | YANG Yuqing, CHEN Yuhuan, LI Chunxiao, LING Xiao, WANG Panpan, GUO Jing, ZHANG Yingying. Effectiveness and safety of Pingxiao capsule (平消胶囊) as adjuvant therapy in treatment of breast cancer: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(5): 851-859. |
| [12] | ZHANG Xinghe, LI Qifu, YI Rong, XING Chonghui, JIN Yuhao, MENG Jiangqiong, FENG Jialei, ZHAO Siwen, LIANG Fanrong, GUO Taipin. Effect of catgut embedding at acupoints versus non-acupoints in abdominal obesity: a randomized clinical trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(4): 780-786. |
| [13] | HUANG Zhaohan, FANG Yuan, WANG Xiaolu, HAN Yue, YU Qi, WANG Tong. Effectiveness of acupuncture-related therapies on schizophrenia: a Bayesian network Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(2): 239-251. |
| [14] | ZHANG Yuehong, DONG Dandan, YAN Youqin, ZHANG Hao, WANG Guangli, ZHOU Wei, LI Wei, QIU Li, LI Tingming, LIU Quan, XIA Ping, MAO Lina, YANG Danlin, YANG Lu, LIAN Fengmei, TONG Xiaolin, BA Yuanming. Effectiveness and safety of Jinshuibao capsules (金水宝胶囊) in treatment of residual cardiopulmonary symptoms in convalescent patients of coronavirus disease 2019: a pilot randomized, double-blind, placebo-controlled clinical trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(1): 134-139. |
| [15] | YAO Yao, ZHAO Zhenni, CHEN Fengqin, LENG Yufei, PANG Xiangtian, XU Xiao, SUN Zhiling. Effectiveness of moxibustion alone on lumbar disc herniation: a Meta-analysis of randomized controlled trials [J]. Journal of Traditional Chinese Medicine, 2023, 43(1): 14-26. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
